Ovoca Bio PLC traded at 6.30 this Friday January 27th, decreasing 0.10 or 1.56 percent since the previous trading session. Looking back, over the last four weeks, Ovoca Bio PLC lost 22.09 percent. Over the last 12 months, its price fell by 42.73 percent. Looking ahead, we forecast Ovoca Bio PLC to be priced at 6.03 by the end of this quarter and at 5.30 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
6.30
Daily Change
-1.56%
Yearly
-42.73%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AstraZeneca 1,357.00 -1.00 -0.07% 22.19%
Great Western Mining Corporation PLC 0.09 0 0% -30.80%


Ovoca Bio PLC
Ovoca Bio plc is a clinical-stage biopharmaceutical company focused on women's health. The Company is developing a treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). It is focused on women's health and identifying candidates in areas of unmet medical need. The Company's lead product, Orenetide (BP-101), is a synthetic peptide administered through nasal spray. The spray delivers the drug to the olfactory and trigeminal nerves in the nasal cavity, where the drug accumulates in the olfactory bulb and further in the brain. It is developing a new treatment for women affected by low libido or sex drive. The Company's subsidiaries include Silver Star Ltd., Bulun LLC, Magsel LLC, IVIX LLC, and OVB (Australia) Pty Ltd, among others. The Company operates in Ireland, the United Kingdom and Russia.